Universität Bielefeld

© Universität Bielefeld

Tumour-Targeting with drug-conjugates

Cryptophycins are a class of 16-membered highly cytotoxicmacrocyclic depsipeptides isolated from cyanobacteria. The biological activity is based on their ability to interact with tubulin. They interfere with microtubule dynamics and preventmicrotubules from forming correctmitotic spindles,which causes cell-cycle arrest and apoptosis. Their strong antiproliferative activities with 100-fold to 1000-fold potency compared with those of paclitaxel and vinblastine have been observed. Cryptophycins are highly promising drug candidates, as their biological activity is not negatively affected by P-glycoprotein, a drug efflux systemcommonly found in multidrug-resistant cancer cell lines and solid tumors. Cryptophycin-52 had been investigated in phase II clinical trials but failed because of its high neurotoxicity. Recently, cryptophycin conjugates with peptides and antibodies have been developed for targeted delivery in tumor therapy.



People involved in this project

Adina Noémi Borbély

Adina Noémi Borbély

Room: F2-264
Phone: +49521-106-2147

E-Mail: adina.borbely@uni-bielefeld.de


Eduard Figueras Agusti

Eduard Figueras Agusti

Room: F2-264
Phone: +49521-106-2147

E-Mail: eduard.figueras@uni-bielefeld.de


Schachtsiek Thomas

Thomas Schachtsiek

Room: F2-264
Phone: +49521-106-2147

E-Mail: t.schachtsiek@uni-bielefeld.de


Jannik Paulus

Jannik Paulus

Room: F2-246
Phone: +49521-106-2145

E-Mail: j.paulus@uni-bielefeld.de


Nils Janson

Nils Janson

Room: F2-270
Phone: +49521-106-2148

E-Mail: n.janson@uni-bielefeld.de